VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

UB-612

Vaccine Information

Vaccine Name: UB-612
Target Pathogen: SARS-CoV-2
Target Disease: COVID-19
Manufacturer: Vaxxinity
Vaccine Ontology ID: VO_0004995
Type: Subunit vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Immunization Route: Intramuscular injection (i.m.)

Host Response

Human Response

Efficacy: Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain.(Guirakhoo et. al 2022)

References

Guirakhoo et. al 2022: Farshad Guirakhoo 1, Shixia Wang 1, Chang Yi Wang 2, Hui Kai Kuo 2, Wen Jiun Peng 2, Hope Liu 2, Lixia Wang 1, Marina Johnson 3, Adam Hunt 3, Mei Mei Hu 1, Thomas P Monath 1, Alexander Rumyantsev 1, David Goldblatt 3. High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. . 2022; ; . [PubMed: 35723969].